

Extensions of the Kermack-McKendrick model MATH 8xyz – Lecture 05

Julien Arino
Department of Mathematics @ University of Manitoba
Maud Menten Institute @ PIMS
julien.arino@umanitoba.ca

Winter 20XX

The University of Manitoba campuses are located on original lands of Anishinaabeg, Ininew, Anisininew, Dakota and Dene peoples, and on the National Homeland of the Red River Métis.

We respect the Treaties that were made on these territories, we acknowledge the harms and mistakes of the past, and we dedicate ourselves to move forward in partnership with Indigenous communities in a spirit of Reconciliation and collaboration.

Outline

The SLIAR model
Computing the final size more efficiently
A variation on the SLIAR model
A model with vaccination
Antiviral resistance
A COVID-19 model



Simple models for containment of a pandemic

Julien Arino^{1,*}, Fred Brauer², P. van den Driessche³, James Watmough⁴ and Jianhong Wu⁵

¹Department of Mathematics, University of Manitoba, Winnipeg,
Manitoba R3T 2N2, Canada

²Department of Mathematics, University of British Columbia,
Vancouver, British Columbia V6T 1Z2, Canada

³Department of Mathematics and Statistics, University of Victoria,
Victoria, British Columbia V8W 3P4, Canada

⁴Department of Mathematics and Statistics, University of New Brunswick,
Fredericton, New Brunswick E3B 5A3, Canada


⁵Department of Mathematics and Statistics, York University,
Toronto. Ontario M3J 1P3. Canada

SIR is a little too simple for many diseases:

► No incubation period

► A lot of infectious diseases (in particular respiratory) have mild and less mild forms depending on the patient

⇒ model with SIR but also L(atent) and (A)symptomatic individuals, in which I are now symptomatic individuals



Basic reproduction number & Final size

We find the basic reproduction number

$$\mathcal{R}_0 = \beta \left(\frac{p}{\alpha} + \frac{\delta(1-p)}{\eta} \right) S_0 = \frac{\beta \rho}{\alpha} S_0 \tag{1}$$

(2)

where


$$\rho = \alpha \left(\frac{p}{\alpha} + \frac{\delta(1-p)}{\eta} \right)$$

The final size relation takes the form

$$S_0(\ln S_0 - \ln S_\infty) = \mathcal{R}_0(S_0 - S_\infty) + rac{\mathcal{R}_0 I_0}{
ho}$$

p. 4 –

Adding treatment






Figure 3. Total number of doses used in a population of 1000 individuals over the course of the outbreak as a function of the mean times to treatment and prophylaxis (in days), for \mathcal{R}_0 = 1.5, with S_0 =999 and I_0 =1.




Figure 4. Total cases as a function of the treatment rates, for $\mathcal{R}_0 = 1.5$, with $S_0 = 999$ and $I_0 = 1$.

5. CONCLUSIONS

Compartmental models facilitate the analysis of sensitivity of the model to errors in measuring parameters or to changes in the control parameters. This is particularly valuable before the beginning of an epidemic when the values of some parameters are only guesses. For example, a sensitivity analysis of our model shows the importance of estimating the parameter p representing the fraction of latent members that will develop symptoms. This parameter is almost impossible to determine accurately, and it is taken to be 2/3 in Longini et al. (2004) and 1/2 in Ferguson et al. (2005). In view of the many uncertainties in estimating parameters for pandemic influenza, it is important to consider a large range of values, and the simplicity of calculation offered by a deterministic compartmental model lends itself to doing this as an initial step before more complicated models such as those of Ferguson et al. (2005) and Longini et al. (2005) are invoked. The calculations reported here involve nothing more complicated than the solution of a system of two transcendental equations.

The SLIAR model Computing the final size more efficiently

A variation on the SLIAR model

A model with vaccination

Antiviral resistance

A COVID-19 model

pp. **159–175**

A FINAL SIZE RELATION FOR EPIDEMIC MODELS

Julien Arino

Department of Mathematics, University of Manitoba Winnipeg, Manitoba R3T 2N2, Canada

FRED BRAHER

Department of Mathematics, University of British Columbia Vancouver, BC V6T 1Z2, Canada

P. VAN DEN DRIESSCHE

Department of Mathematics and Statistics, University of Victoria Victoria, B.C. V8W 3P4, Canada

James Watmough

Department of Mathematics and Statistics, University of New Brunswick Fredericton, N.B. E3B 5A3, Canada

JIANHONG WU

Department of Mathematics and Statistics, York University Toronto, Ontario M3J 1P3, Canada

(Communicated by Zhilan Feng)

A method for computing \mathcal{R}_0 in epidemic models

► This method is not universal! It works in a relatively large class of models, but not everywhere

▶ If it doesn't work, the next generation matrix method does work, **but** should be considered only for obtaining the reproduction number, not to deduce LAS

► Here, I change the notation in the paper, for convenience

Standard form of the system

Suppose system can be written in the form

$$S' = b(S, I, R) - DS\beta(S, I, R)hI$$
 (3a)
 $I' = \Pi DS\beta(S, I, R)hI - VI$ (3b)
 $R' = f(S, I, R) + WI$ (3c)

where $\pmb{S} \in \mathbb{R}^m$, $\pmb{I} \in \mathbb{R}^n$ and $\pmb{R} \in \mathbb{R}^k$ are susceptible, infected and removed compartments, respectively

IC are > 0 with at least one of the components of I(0) positive

$$S' = b(S, I, R) - DS\beta(S, I, R)hI$$
 (3a)

- ▶ b: $\mathbb{R}_+^m \times \mathbb{R}_+^n \times \mathbb{R}_+^k \to \mathbb{R}^m$ continuous function encoding recruitment and death of uninfected individuals
- ▶ $D \in \mathbb{R}^{m \times m}$ diagonal with diagonal entries $\sigma_i > 0$ the relative susceptibilities of susceptible compartments, with convention that $\sigma_1 = 1$
- Scalar valued function $\beta: \mathbb{R}_+^m \times \mathbb{R}_+^n \times \mathbb{R}_+^k \to \mathbb{R}_+$ represents infectivity, with, e.g., $\beta(S, I, R) = \beta$ for mass action
- $h \in \mathbb{R}^n$ row vector of relative horizontal transmissions

$$I' = \Pi DS \beta(S, I, R) h I - \forall I$$
 (3b)

- ▶ $\Pi \in \mathbb{R}^{n \times m}$ has (i,j) entry the fraction of individuals in j^{th} susceptible compartment that enter i^{th} infected compartment upon infection
- ▶ $D \in \mathbb{R}^{m \times m}$ diagonal with diagonal entries $\sigma_i > 0$ the relative susceptibilities of susceptible compartments, with convention that $\sigma_1 = 1$
- Scalar valued function $\beta: \mathbb{R}_+^m \times \mathbb{R}_+^n \times \mathbb{R}_+^k \to \mathbb{R}_+$ represents infectivity, with, e.g., $\beta(S, I, R) = \beta$ for mass action
- $h \in \mathbb{R}^n$ row vector of relative horizontal transmissions
- $V \in \mathbb{R}^{n \times n}$ describes transitions between infected states and removals from these states due to recovery or death

$$\mathbf{R}' = f(\mathbf{S}, \mathbf{I}, \mathbf{R}) + W\mathbf{I} \tag{3c}$$

- ▶ $f: \mathbb{R}_+^m \times \mathbb{R}_+^n \times \mathbb{R}_+^k \to \mathbb{R}^k$ continuous function encoding flows into and out of removed compartments because of immunisation or similar processes
- ▶ W ∈ $\mathbb{R}^{k \times n}$ has (i,j) entry the rate at which individuals in the j^{th} infected compartment move into the i^{th} removed compartment

p. 14

Suppose $\textbf{\textit{E}}_0$ is a locally stable disease-free equilibrium (DFE) of the system without disease, i.e., an EP of

$$S' = b(S, 0, R)$$

 $R' = f(S, 0, R)$

Theorem 1

Let

$$\mathcal{R}_0 = \beta(\mathbf{S}_0, 0, \mathbf{R}_0) \mathbf{h} \mathsf{V}^{-1} \mathbf{\Pi} \mathbf{D} \mathbf{S}_0 \tag{4}$$

- ▶ If $\mathcal{R}_0 < 1$, the DFE \mathbf{E}_0 is a locally asymptotically stable EP of (3)
- ▶ If $\mathcal{R}_0 > 1$, the DFE \mathbf{E}_0 of (3) is unstable

If no demography (epidemic model), then just \mathcal{R}_0 , of course

Final size relations

Assume no demography, then system should be writeable as

$$S' = -DS\beta(S, I, R)hI$$
 (5a)
 $I' = \Pi DS\beta(S, I, R)hI - VI$ (5b)
 $R' = WI$ (5c)

For $w(t) \in \mathbb{R}^n_+$ continuous, define

$$w_{\infty} = \lim_{t \to \infty} w(t)$$
 and $\hat{w} = \int_0^{\infty} w(t) \ dt$

p. 16 -

Define the row vector

$$\mathbb{R}^m \ni \Gamma = (\Gamma_1, \dots, \Gamma_m) = \beta(S_0, 0, R_0) h \mathsf{V}^{-1} \Pi D$$

then

$$\mathcal{R}_0 = \mathbf{\Gamma} \boldsymbol{S}(0)$$

Suppose incidence is mass action, i.e., $\beta(S, I, R) = \beta$ and m > 1

Then for $i=1,\ldots,m$, express $\boldsymbol{S}_i(\infty)$ as a function of $\boldsymbol{S}_1(\infty)$ using

$$oldsymbol{S}_i(\infty) = oldsymbol{S}_i(0) \left(rac{oldsymbol{S}_1(\infty)}{oldsymbol{S}_1(0)}
ight)^{\sigma_i/\sigma_1}$$

then substitute into

$$egin{aligned} rac{1}{\sigma_i} \ln \left(rac{m{\mathcal{S}}_i(0)}{m{\mathcal{S}}_i(\infty)}
ight) &= \Gamma m{D}^{-1} \left(m{\mathcal{S}}(0) - m{\mathcal{S}}(\infty)
ight) + eta m{h} m{V}^{-1} m{I}(0) \ &= rac{1}{\sigma_1} \ln \left(rac{m{\mathcal{S}}_1(0)}{m{\mathcal{S}}_1(\infty)}
ight) \end{aligned}$$

which is a final size relation for the general system when $S_i(0) > 0$

If incidence is mass action and $\it m=1$ (only one susceptible compartment), reduces to the KMK form

$$\ln\left(\frac{S_0}{S_\infty}\right) = \frac{\mathcal{R}_0}{S_0}(S_0 - S_\infty) + \beta \mathbf{h} \mathsf{V}^{-1} \mathbf{I}_0 \tag{6}$$

p. 19 -

In the case of more general incidence functions, the final size relations are inequalities of the form, for i = 1, ..., m,

$$\ln\left(rac{oldsymbol{S}_i(0)}{oldsymbol{S}_i(\infty)}
ight) \geq \sigma_i \Gamma oldsymbol{D}^{-1}\left(oldsymbol{S}(0) - oldsymbol{S}(\infty)
ight) + \sigma_i eta(K)oldsymbol{h} \mathsf{V}^{-1}oldsymbol{I}(0)$$

where K is the initial total population

The SLIAR model Computing the final size more efficiently

A variation on the SLIAR model


A model with vaccination Antiviral resistance

A COVID-19 model

The SLIAR model

▶ Paper we have already seen: Arino, Brauer, PvdD, Watmough & Wu. Simple models for containment of a pandemic, *Journal of the Royal Society Interface* (2006)

ightharpoonup However, suppose additionally that L are also infectious



Here, $\mathbf{S} = S$, $\mathbf{I} = (L, I, A)^T$ and $\mathbf{R} = R$, so m = 1, n = 3 and

$$h = [\varepsilon \ 1 \ \delta], \quad D = 1, \quad \Pi = \begin{pmatrix} 1 \\ 0 \\ 0 \end{pmatrix} \quad \text{and} \quad V = \begin{pmatrix} \kappa & 0 & 0 \\ -p\kappa & \alpha & 0 \\ -(1-p)\kappa & 0 & \eta \end{pmatrix}$$

Incidence is mass action so $\beta(\mathbf{E}_0) = \beta$ and thus

$$\mathcal{R}_{0} = \beta \mathbf{h} \mathsf{V}^{-1} \mathbf{\Pi} \mathbf{D} \mathbf{S}_{0}$$

$$= \beta \left[\varepsilon \ 1 \ \delta \right] \begin{pmatrix} 1/\kappa & 0 & 0 \\ p/\alpha & 1/\alpha & 0 \\ (1-p)/\eta & 0 & 1/\eta \end{pmatrix} \begin{pmatrix} 1 \\ 0 \\ 0 \end{pmatrix} S_{0}$$

$$= \beta S_{0} \left(\frac{\varepsilon}{\kappa} + \frac{p}{\alpha} + \frac{\delta(1-p)}{\alpha} \right)$$

For final size, since m = 1, we can use (6):

$$\ln\left(rac{S_0}{S_{\infty}}
ight) = rac{\mathcal{R}_0}{S_0}(S_0 - S_{\infty}) + eta oldsymbol{h} \mathsf{V}^{-1} oldsymbol{I}_0$$

Suppose $I_0 = (0, I_0, 0)$, then

$$\ln\left(\frac{S_0}{S_{\infty}}\right) = \mathcal{R}_0 \frac{S_0 - S_{\infty}}{S_0} + \frac{\beta}{\alpha} I_0$$

If $I_0 = (L_0, I_0, A_0)$, then

$$\ln\left(\frac{S_0}{S_\infty}\right) = \mathcal{R}_0 \frac{S_0 - S_\infty}{S_0} + \beta \left(\frac{\varepsilon}{\kappa} + \frac{p}{\alpha} + \frac{\delta(1-p)}{\eta}\right) L_0 + \frac{\beta \delta}{\eta} A_0 + \frac{\beta}{\alpha} I_0$$


The SLIAR model Computing the final size more efficiently A variation on the SLIAR model

A model with vaccination

Antiviral resistance

A COVID-19 model

A model with vaccination



A model with vaccination

Fraction γ of S_0 are vaccinated before the epidemic; vaccination reduces probability and duration of infection, infectiousness and reduces mortality

$$S_{U}' = -\beta S_{U}[I_{U} + \sigma_{I}I_{V}]$$

$$S_{V}' = -\sigma_{S}\beta S_{V}[I_{U} + \sigma_{I}I_{V}]$$

$$L_{U}' = \beta S_{U}[I_{U} + \sigma_{I}I_{V}] - \kappa_{U}L_{U}$$

$$I_{V}' = \sigma_{S}\beta S_{V}[I_{U} + \sigma_{I}I_{V}] - \kappa_{V}L_{V}$$

$$I_{U}' = \kappa_{U}L_{U} - \alpha_{U}I_{U}$$

$$I_{V}' = \kappa_{V}L_{V} - \alpha_{V}I_{V}$$

$$R' = f_{U}\alpha_{U}I_{I} + f_{V}\alpha_{V}I_{V}$$

$$(7a)$$

$$(7b)$$

$$(7c)$$

$$(7d)$$

$$(7e)$$

$$I_{V}' = \kappa_{V}L_{V} - \alpha_{V}I_{V}$$

$$(7f)$$

with
$$S_U(0) = (1 - \gamma)S_0$$
 and $S_V(0) = \gamma S_0$

Here, m = 2, n = 4,

$$m{h} = [0\ 0\ 1\ \sigma_I], \quad m{D} = egin{pmatrix} 1 & 0 \ 0 & \sigma_S \end{pmatrix}, \quad m{\Pi} = egin{pmatrix} 1 & 0 \ 0 & 1 \ 0 & 0 \ 0 & 0 \end{pmatrix}$$

and

$$V = \begin{pmatrix} \kappa_{U} & 0 & 0 & 0 \\ 0 & \kappa_{V} & 0 & 0 \\ -\kappa_{U} & 0 & \alpha_{U} & 0 \\ 0 & -\kappa_{V} & 0 & \alpha_{V} \end{pmatrix}$$

p. 27

So

$$\Gamma = \left[rac{eta}{lpha_{\mathcal{U}}} \, rac{\sigma_{\mathcal{I}} \sigma_{\mathcal{S}} eta}{lpha_{\mathcal{V}}}
ight], \quad \mathcal{R}_{c} = S_{0} eta \left(rac{1-\gamma}{lpha_{\mathcal{U}}} + rac{\sigma_{\mathcal{I}} \sigma_{\mathcal{S}} \gamma}{lpha_{\mathcal{V}}}
ight)$$

and the final size relation is

$$\ln\left(\frac{(1-\gamma)S_U(0)}{S_U(\infty)}\right) = \frac{\beta}{\alpha_U}[(1-\gamma)S_U(0) - S_U(\infty)] + \frac{\sigma_I\beta}{\alpha_V}[\gamma S_V(0) - S_V(\infty)] + \frac{\beta}{\alpha_U}I_0$$

$$S_V(\infty) = \gamma S_U(0) \left(\frac{S_U(\infty)}{(1-\gamma)S_0} \right)^{\sigma_S}$$

The SLIAR model
Computing the final size more efficiently
A variation on the SLIAR model

A model with vaccination

Antiviral resistance

A COVID-19 model

BMC Infectious Diseases



Research article

Open Access

Antiviral resistance during pandemic influenza: implications for stockpiling and drug use

Julien Arino^{1,2}, Christopher S Bowman^{2,3} and Seyed M Moghadas*^{2,4,5}

Address: ¹Department of Mathematics, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada, ²Institute for Biodiagnostics, National Research Council Canada, Winnipeg, Manitoba R3B 1Y6, Canada, ³Department of Electrical and Computer Engineering, University of Manitoba, Winnipeg, Manitoba R3T 5V6, Canada, ⁴Department of Mathematics and Statistics, University of Winnipeg, Winnipeg, Manitoba R3B 2E9, Canada and ³Department of Statistics, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada

Email: Julien Arino - arinoj@cc.umanitoba.ca; Christopher S Bowman - chris.bowman@nrc-cnrc.gc.ca; Seyed M Moghadas* - seyed.moghadas@nrc-cnrc.gc.ca

* Corresponding author

Published: 22 January 2009


Received: 5 August 2008 Accepted: 22 January 2009

Adapting treatment to counter emergence of resistance

This work was undertaken at the request of the Public Health Agency of Canada during the pandemic preparadness phase prior to the 2009 p-H1N1 pandemic

Problem: we have antivirals to use against influenza, either prophylactically or curatively. Using these antivirals may promote the emergence of antiviral-resistant strains. How do we minimise this risk?

p. 30



The SLIAR model
Computing the final size more efficiently
A variation on the SLIAR model
A model with vaccination
Antiviral resistance
A COVID-19 model



Contents lists available at ScienceDirect


Infectious Disease Modelling

journal homepage: www.keaipublishing.com/idm



A simple model for COVID-19

Julien Arino a, b, c, *, Stéphanie Portet a






b Centre for Disease Modelling, Canada



^c Canadian COVID-19 Mathematical Modelling Task Force, Canada

Extends the SLIAR model to take into account non-exponentially distributed stage durations (see course 02)


The original model (well, almost the first one)



p. 34

Reinterpreting terms

Here D stands for detected, U is undetected



Working out when the first COVID-19 case occurred

- ▶ Details of emergence and precise timeline before amplification started unknown
- ► Amplification in Wuhan
 - ► Cluster of pneumonia cases mostly related to the Huanan Seafood Market
 - ▶ 27 December 2019: first report to local government
 - ▶ 31 December 2019: publication
 - ▶ 8 January 2020: identification of SARS-CoV-2 as causative agent
 - ightharpoonup \sim 23 January 2020: lockdown Wuhan and Hubei province + face mask mandates
- ▶ By 2020-01-29, virus in all provinces of mainland CHN

Evidence of earlier spread

- ► Report to Wuhan authorities on 27 December 2019
- ► First export detections in Thailand and Japan on 13 and 16 January 2020 (with actual importations on 8 and 6 January)
- ⇒ amplification must have been occuring for a while longer
- ► France: sample taken from 42-year-old male (last foreign travel to Algeria in August 2019) who presented to ICU on 27 December 2019
- ► Retrospective studies in United Kingdom and Italy also showed undetected COVID-19 cases in prepandemic period

Untangling the first case issue

- ▶ Robert, Rossman & Jaric. Dating first cases of COVID-19. *PLoS Pathogens* (2021) Find likely timing of first case of COVID-19 in China as November 17 (95% CI October 4)
- ▶ Pekar, Worobey, Moshiri, Scheffler & Wertheim. Timing the SARS-CoV-2 index case in Hubei province. *Science* (2021)

Period between mid-October and mid-November 2019 is plausible interval when the first case of SARS-CoV-2 emerged in Hubei province

Important when trying to understand global spread, so let me illustrate with the model I used, taking into account model evolution since

Back-calculating the start of spread (example of China)


Cumulative confirmed case counts in China as reported to WHO was $\emph{c}=547$ cases on $\emph{t}_\emph{c}=2020\text{-}01\text{-}22$

Let u be a point in parameter space. Solve ODE numerically over [0, t], with S(0) the population of China, $L_1(0)=1$ and other state variables 0. This gives a solution $x(t,t_0=0,u)$

Extracting $L_2(t, t_0 = 0, u)$ from this solution, obtain cumulative number of new detections as

$$C(t) = \int_{t_0=0}^{t} p \varepsilon_2 L_2(s, t_0, u) \ ds$$

Let t^* be s.t. $C(t^*) = 547$; then $t_i = 2020 - 01 - 22 - t^*$



Bibliography I

- J. Arino, C.S. Bowman, and S.M. Moghadas. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use. *BMC Infectious Diseases*, 9(8), 2009.
- J. Arino, F. Brauer, P. van den Driessche, J. Watmough, and J. Wu. Simple models for containment of a pandemic. *Journal of the Royal Society Interface*, 3(8):453–457, 2006.
- J. Arino, F. Brauer, P. van den Driessche, J. Watmough, and J. Wu. A final size relation for epidemic models. *Mathematical Biosciences and Engineering*, 4(2):159–175, 2007.
- J. Arino and S. Portet. A simple model for COVID-19. *Infectious Disease Modelling*, 5:309–315, 2020.